Figure 2.

Distribution of cohorts’ AEs over time (left) and of cohorts’ total size (right). Distribution over time does not include incomplete AEs for which no date was specifically registered or AEs reported prior to 2011; AEs dated prior to a drug’s approval may reflect reports from preapproval studies and clinical trials. The reduction of AE numbers for 2017 is explained by the fact that the full dataset for that year was not yet released by FAERS at the time this analysis took place. FDA approved ipilimumab on 2011 and nivolumab on December 2014.